Zika virus research models

Kublin, Jessica; Whitney, James B.

doi:10.1016/j.virusres.2017.07.025

Cited by 9 publications

(3 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of Zika vaccine candidates have been tested in various animal models from mouse to monkey as has been previously described ( Kublin and Whitney, 2017 , Ming et al, 2016 ). Monkey models have experimental limitations such as high cost and difficulty in obtaining a large number of animals for a significant study, while the commonly used immunodeficient AG129 mice do not generate sufficient cellular and humoral immunity due to lack of IFN α/β/γ receptors.…”

Section: Discussionmentioning

confidence: 99%

A DNA Vaccine Protects Human Immune Cells against Zika Virus Infection in Humanized Mice

Abraham

et al. 2017

EBioMedicine

View full text Add to dashboard Cite

A DNA vaccine encoding prM and E protein has been shown to induce protection against Zika virus (ZIKV) infection in mice and monkeys. However, its effectiveness in humans remains undefined. Moreover, identification of which immune cell types are specifically infected in humans is unclear. We show that human myeloid cells and B cells are primary targets of ZIKV in humanized mice. We also show that a DNA vaccine encoding full length prM and E protein protects humanized mice from ZIKV infection. Following administration of the DNA vaccine, humanized DRAG mice developed antibodies targeting ZIKV as measured by ELISA and neutralization assays. Moreover, following ZIKV challenge, vaccinated animals presented virtually no detectable virus in human cells and in serum, whereas unvaccinated animals displayed robust infection, as measured by qRT-PCR. Our results utilizing humanized mice show potential efficacy for a targeted DNA vaccine against ZIKV in humans.

show abstract

Section: Discussionmentioning

confidence: 99%

A DNA Vaccine Protects Human Immune Cells against Zika Virus Infection in Humanized Mice

Abraham

et al. 2017

EBioMedicine

View full text Add to dashboard Cite

show abstract

“…Mouse, Rhesus monkey, Cynomolgus monkey (Bradley and Nagamine, 2017;Chiu et al, 2017;Kublin and Whitney, 2018;Lum et al, 2018;Seferovic et al, 2018;Terzian et al, 2018;Berry et al, 2019;Luo et al, 2020;Kim et al, 2022) West Nile virus One study (model development and characterization)…”

Section: Francisella Tularensismentioning

confidence: 99%

Marmosets as models of infectious diseases

Herron,

Laws,

Nelson

2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Animal models of infectious disease often serve a crucial purpose in obtaining licensure of therapeutics and medical countermeasures, particularly in situations where human trials are not feasible, i.e., for those diseases that occur infrequently in the human population. The common marmoset (Callithrix jacchus), a Neotropical new-world (platyrrhines) non-human primate, has gained increasing attention as an animal model for a number of diseases given its small size, availability and evolutionary proximity to humans. This review aims to (i) discuss the pros and cons of the common marmoset as an animal model by providing a brief snapshot of how marmosets are currently utilized in biomedical research, (ii) summarize and evaluate relevant aspects of the marmoset immune system to the study of infectious diseases, (iii) provide a historical backdrop, outlining the significance of infectious diseases and the importance of developing reliable animal models to test novel therapeutics, and (iv) provide a summary of infectious diseases for which a marmoset model exists, followed by an in-depth discussion of the marmoset models of two studied bacterial infectious diseases (tularemia and melioidosis) and one viral infectious disease (viral hepatitis C).

show abstract

“…Since the last major epidemic in the Americas in 2016, great efforts have been conducted in research of prevention and therapy development, but currently there is still no approved vaccine or specific antiviral against ZIKV. [10][11][12][13] Clinical treatment of infected patients consists of only supportive care, and the best way to prevent ZIKV infection is to avoid mosquito bites. On the other hand, increased air travel means that it is more likely that a virus could be imported from one country into other countries in the tropical and subtropical regions, 14 which is capable of establishing imported and local transmission.…”

mentioning

confidence: 99%